ICH Q1AICH Q1A(R2) Stability Testing of New Drug Substances and Products
ICH Q1A(R2) is the harmonised framework that tells sponsors what stability data a new drug substance or drug product registration needs — which storage conditions to test at, how often to pull samples, and what counts as a significant change that triggers extra testing.

On this page · 9 sections
- 1Purpose and scope of the guideline
- 2Stress testing of the drug substance
- 3Formal stability study design — batches, container, specification
- 4Storage conditions: long-term, intermediate, accelerated
- 5Testing frequency
- 6Significant change — the trigger for intermediate testing
- 7Data evaluation, re-test period, and shelf-life extrapolation
- 8Storage statements and labelling
- 9How Q1A(R2) relates to Q1B, Q1C, Q1D, and Q1E
How does ICH Q1A apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01Purpose and scope of the guideline
Q1A(R2) states its objective plainly: it defines the stability data package for a new drug substance or drug product that is sufficient for a registration application within the three original ICH regions — the European Community, Japan, and the United States — while leaving flexibility for alternative approaches when there are scientifically justifiable reasons. It does not claim to cover testing needed for registration in, or export to, other parts of the world, though in practice its framework is referenced far more broadly than its original three-region scope.
The guideline's stated scope is registration applications for new molecular entities and their associated drug products. It explicitly does not set out to cover abbreviated or abridged applications, variations, or clinical trial applications, and it does not get into the sampling and testing detail for particular dosage forms in their proposed container closures — that detail sits in ICH Q1C (new dosage forms) and, for biotechnological/biological products, in ICH Q5C.
The General Principles section ties the whole guideline to a single purpose: stability testing exists to show how the quality of a drug substance or drug product varies over time under temperature, humidity, and light, and to use that evidence to set a re-test period for the drug substance (or a shelf life for the drug product) together with the recommended storage conditions. Q1A(R2) addresses climatic zones I and II specifically; the related guideline ICH Q1F addressed the stability data package implications for climatic zones III and IV, and the intermediate condition in Q1A(R2) was itself revised to harmonise with Q1F.
02Stress testing of the drug substance
Stress testing sits ahead of the formal stability programme and serves a different purpose: it helps identify likely degradation products, establish degradation pathways and the molecule's intrinsic stability, and validate that the analytical procedures chosen are stability-indicating — meaning they can distinguish the active from its degradation products rather than reporting a number that looks the same whether the material is fresh or degraded.
Q1A(R2) describes stress testing as likely to be carried out on a single batch of the drug substance, covering temperature effects in 10°C increments above the accelerated testing condition (for example 50°C, 60°C), humidity of 75% RH or greater where appropriate, oxidation, and photolysis, plus the substance's susceptibility to hydrolysis across a wide pH range in solution or suspension. Photostability testing is described as an integral part of stress testing, with standard conditions set out in the companion guideline ICH Q1B.
The guideline also notes a practical limit: it may not be necessary to specifically examine for certain degradation products once it has been demonstrated that they are not formed under accelerated or long-term storage conditions. Results from stress testing form part of the information submitted to regulatory authorities, but they are a separate exercise from the formal, protocol-driven stability studies described below.
03Formal stability study design — batches, container, specification
For both the drug substance and the drug product, Q1A(R2) calls for formal stability data on at least three primary batches. For the drug substance, batches should be manufactured to at least pilot scale by the same synthetic route and using a method of manufacture and procedure that simulates the final production process, and should be representative of production-scale quality. For the drug product, the primary batches should carry the same formulation and be packaged in the same container closure system proposed for marketing; two of the three should be at least pilot scale, with the third permitted to be smaller if justified, and where possible the batches should draw on different batches of the drug substance.
Container closure systems used in the formal studies should be the same as, or simulate, the packaging proposed for storage, distribution, and marketing — including, for the drug product, any secondary packaging and container labelling where appropriate. Specification content (the list of tests, analytical procedures, and acceptance criteria) is addressed by ICH Q6A and Q6B, with degradation-product limits addressed by Q3A for drug substances and Q3B for drug products; stability studies should test whichever physical, chemical, biological, and microbiological attributes are susceptible to change on storage and likely to affect quality, safety, or efficacy, using validated stability-indicating analytical procedures.
Stability studies should normally be performed on each individual strength and container size of the drug product, unless a bracketing or matrixing reduced design is applied and justified — the reduced-design approach is developed in its own guideline, ICH Q1D.
04Storage conditions: long-term, intermediate, accelerated
Q1A(R2)'s general-case table for both drug substances and drug products sets long-term storage at 25°C ± 2°C / 60% RH ± 5% RH or, as an applicant-chosen alternative, 30°C ± 2°C / 65% RH ± 5% RH, each covering a minimum of 12 months' data at the time of submission. The accelerated condition is 40°C ± 2°C / 75% RH ± 5% RH for a minimum of 6 months. The intermediate condition is 30°C ± 2°C / 65% RH ± 5% RH, with a minimum of 6 months' data; the guideline is explicit that if 30°C/65% RH is chosen as the long-term condition, there is no separate intermediate condition, because long-term and intermediate would be the same.
| Study | Storage condition (general case) | Minimum data at submission |
|---|---|---|
| Long term | 25°C ± 2°C/60% RH ± 5% RH or 30°C ± 2°C/65% RH ± 5% RH (applicant's choice) | 12 months |
| Intermediate | 30°C ± 2°C/65% RH ± 5% RH (not applicable if 30°C/65% RH is the long-term condition) | 6 months |
| Accelerated | 40°C ± 2°C/75% RH ± 5% RH | 6 months |
Separate tables apply for drug substances and drug products intended for refrigerated storage (long term 5°C ± 3°C for 12 months; accelerated 25°C ± 2°C/60% RH ± 5% RH for 6 months) and for freezer storage (long term −20°C ± 5°C for 12 months, with no accelerated condition and a single-batch elevated-temperature study instead used to address short-term excursions). Material intended for storage below −20°C is treated case by case. Drug products packaged in impermeable containers are not a moisture concern and can be studied under any controlled or ambient humidity; aqueous products in semi-permeable containers get their own table (long term 25°C/40% RH or 30°C/35% RH; intermediate 30°C/65% RH; accelerated 40°C/NMT 25% RH) built around evaluating water loss, including a published table of water-loss-rate ratios for deriving results at a reference humidity from data generated at an alternative one.
05Testing frequency
For long-term studies, Q1A(R2) sets the baseline cadence for a substance or product with a proposed re-test period or shelf life of at least 12 months: testing every 3 months over the first year, every 6 months over the second year, and annually thereafter through the proposed re-test period or shelf life.
At the accelerated condition, a minimum of three time points from a 6-month study is recommended, including the initial and final points (for example 0, 3, and 6 months). Where development experience suggests accelerated results are likely to approach the significant-change criteria, the guideline recommends increased testing — either additional samples at the final time point or a fourth time point in the design.
When significant change at the accelerated condition triggers intermediate-condition testing, a minimum of four time points from a 12-month study is recommended, including initial and final points (for example 0, 6, 9, and 12 months), with the initial submission including at least 6 months of that 12-month intermediate dataset.
06Significant change — the trigger for intermediate testing
"Significant change" is the term that decides whether an applicant must add intermediate-condition testing on top of long-term and accelerated data, and the guideline defines it differently for drug substances and drug products. For a drug substance, significant change is defined simply as failure to meet its specification.
For a drug product, Q1A(R2) sets out a more detailed, multi-part definition of significant change: a 5% change in assay from its initial value (or failure to meet the acceptance criteria for potency when biological or immunological procedures are used); any degradation product exceeding its acceptance criterion; failure to meet acceptance criteria for appearance, physical attributes, and functionality tests such as colour, phase separation, resuspendibility, caking, hardness, or dose delivery per actuation (while noting that some physical changes — softening of suppositories, melting of creams — can be expected under accelerated conditions); and, as appropriate for the dosage form, failure to meet the pH acceptance criterion or failure to meet the dissolution acceptance criteria for 12 dosage units.
For products packaged in semi-permeable containers, a 5% loss of water from its initial value is treated as significant change after the equivalent of 3 months' storage at 40°C/NMT 25% RH — though for small containers (1 mL or less) or unit-dose products, a higher water loss may be acceptable if justified. The guideline also draws a distinction for products stored at 25°C/40% RH long term: if significant change other than water loss occurs at the accelerated condition, intermediate-condition testing is called for, but significant water loss alone at the accelerated condition does not by itself require intermediate testing, provided data support that the product will not lose significant water over its proposed shelf life at 25°C/40% RH.
07Data evaluation, re-test period, and shelf-life extrapolation
The Evaluation sections for both drug substance and drug product describe the same underlying statistical logic. The purpose of the stability study is to establish, from testing a minimum of three batches, a re-test period (drug substance) or shelf life (drug product) applicable to future batches manufactured under similar circumstances. Where degradation and variability are small enough that the requested period is clearly supported on inspection of the data, the guideline says a full formal statistical analysis is normally unnecessary, provided the omission is justified.
Where a quantitative attribute is expected to change over time, one approach described is to determine the time at which the 95% one-sided confidence limit for the mean degradation curve intersects the acceptance criterion. If batch-to-batch variability is shown to be small (for example by testing the significance of differences in slopes and intercepts across batches, with a stated example of p > 0.25 as a level for not rejecting poolability), the data can be combined into a single estimate; if pooling is not appropriate, the overall re-test period or shelf life should be based on the minimum time any batch could be expected to remain within its acceptance criteria. The nature of the degradation relationship (linear, quadratic, or cubic, on an arithmetic or logarithmic scale) determines how the data should be modelled, and goodness-of-fit should be tested statistically.
Q1A(R2) allows limited extrapolation of real-time long-term data beyond the observed range to extend the re-test period or shelf life at approval, if justified — the justification should draw on the known degradation mechanism, accelerated results, the goodness of fit of the chosen mathematical model, batch size, and any supporting stability data, with the explicit caveat that extrapolation assumes the same degradation relationship continues beyond the observed data. Evaluation should cover not just assay but also degradation products and other relevant attributes. The guideline does not state a specific numeric cap (such as a maximum multiple of the observed data or a fixed additional-months limit) on extrapolation within its own text; that level of worked-example detail sits in the companion evaluation guideline, ICH Q1E.
Where available long-term data do not yet cover the proposed re-test period or shelf life at the time of approval, Q1A(R2) requires a post-approval stability commitment: either continuing studies on at least three production batches already on test, adding further production batches to reach a total of three if fewer are on test, or placing the first three production batches on long-term stability if none were included in the submission — in each case carrying the studies through the proposed re-test period or shelf life using the same protocol as the primary batches unless otherwise justified.
08Storage statements and labelling
The guideline requires a storage statement for labelling, established in accordance with relevant national or regional requirements and based on the stability evaluation performed. Where applicable, specific handling instructions should be given — for example for drug substances that cannot tolerate freezing — and Q1A(R2) specifically cautions against vague terms such as "ambient conditions" or "room temperature." A re-test period should be derived from the stability data, and a retest date displayed on the container label where appropriate.
Frequently asked questions
Q.Does ICH Q1A(R2) apply to generic or abbreviated applications?+
Q1A(R2) states that its scope is registration applications for new molecular entities and their associated drug products, and that it does not currently seek to cover information submitted for abbreviated or abridged applications, variations, or clinical trial applications — though its stability-testing framework is widely used as a reference point beyond that stated scope.
Q.What is the difference between the intermediate condition and the accelerated condition?+
The accelerated condition (40°C ± 2°C/75% RH ± 5% RH, general case) is used routinely as part of the standard six-month study design. The intermediate condition (30°C ± 2°C/65% RH ± 5% RH, general case) is only required if significant change occurs at the accelerated condition during the long-term study at 25°C/60% RH; if the applicant chooses 30°C/65% RH as the long-term condition itself, there is no separate intermediate condition.
Q.Is there a fixed maximum extrapolation period in Q1A(R2)?+
Q1A(R2) permits limited extrapolation of long-term data beyond the observed range, if scientifically justified by the degradation mechanism, accelerated results, model fit, batch size, and supporting data, but the guideline's own text does not state a specific numeric cap. The detailed statistical approach to extrapolation is developed further in ICH Q1E.
Q.Does significant change mean the same thing for drug substances and drug products?+
No. For a drug substance, Q1A(R2) defines significant change simply as failure to meet specification. For a drug product, it is a multi-part definition covering a 5% assay change, any degradation product exceeding its acceptance criterion, failure of physical/functionality attributes, and, as appropriate, pH or dissolution failures — with a separate 5% water-loss threshold for semi-permeable container products.
Primary sources
Further reading
- ICH Q1A Stability Storage ConditionsClimatic-zone storage condition detail in the V5 glossary.
- Bracketing and Matrixing (ICH Q1D)The reduced stability-design guideline Q1A(R2) permits when justified.
- ICH Q3A/Q3B ImpuritiesDegradation-product thresholds referenced by Q1A(R2)'s specification sections.
- Expiry vs Retest DateHow the re-test period and shelf-life concepts from Q1A(R2) play out operationally.
- Stability ProgramRunning a Q1A(R2)-aligned stability programme day to day.
Want to see how ICH Q1A could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
